Our client:

NetScientific is a publicly listed, transatlantic IP Commercialisation group with a primary focus on digital health, diagnostics and therapeutics. The company is an active investor providing extensive management support.


The challenge:

The RSA Group was appointed to find a new CEO for NetScientific after the previous incumbent left the company. As NetScientific is a public company, filling such a role can be particularly challenging as the new appointee would need to be able to maintain the confidence of existing strategic investors whilst attracting new ones. The company also had planned an upcoming funding round and was going through a business turnaround.


Furthermore, the CEO needed to be confident across diagnostics, devices and data, have international capability and credibility, and a vision for technologies and personalised medicine. The consultants needed to identify a small pool of appropriate candidates and compare skills so that decisions could be made quickly.


How our approach made a difference:

Knowing that UK talent was already in high demand, we began by conducting a rapid global search, including public and private companies in international tech, finance and biotech. A shortlist of candidates, with full due diligence, was produced in just four weeks, enabling the Board to make rapid, informed decisions and to move through the selection process with confidence. RSA gave its full support to the Chairman and non-execs throughout the process and, as a result, an appointment was made just eight weeks after RSA was appointed. 


The new CEO was a former VP at Merck and Novartis, previously a biotech CEO in Denmark and a qualified clinician. His strong credentials made him ideal for the challenges of the role.


Reference from Sir Richard Sykes, “I have worked successfully with RSA in senior level recruitment in Life Sciences. I would recommend RSA for their approach to, and services for, executive search in the Life Sciences”

Share this: